Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02612194 | LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | terminated | Phase 2 | 8 | Wake Forest University Health SciencesOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT04060342 |
| terminated |
| Phase 1 |
| 61 |
| GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY |
| 2 |
| Aug 18, 2022 |
| clinicaltrials |
| NCT02735512 | MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer | terminated | — | 10 | University of Southern CaliforniaOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT01732107 | Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression | terminated | Phase 2 | 13 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03718741 | Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.(Bladder-Aid) | terminated | N/A | 7 | Istituto Clinico HumanitasOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT02164942 | LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer | terminated | — | 6 | Wake Forest University Health SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT) | terminated | Early Phase 1 | 2 | University Health Network, TorontoOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | terminated | — | 13 | Indiana UniversityOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | terminated | Phase 2 | 3 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | terminated | N/A | 19 | Emory UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01126749 | Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 1 / Phase 2 | 92 | Eisai Inc.INDUSTRY | 6 | Feb 28, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | terminated | Phase 2 | 77 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma | terminated | Phase 2 | 6 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03389438 | Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma | terminated | Phase 2 | 6 | Beijing Huanxing Cancer HospitalOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants | terminated | Phase 1 / Phase 2 | 24 | Hoffmann-La RocheINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | terminated | Phase 3 | 62 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT04273724 | Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer | terminated | N/A | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | terminated | Phase 3 | 118 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | terminated | Phase 2 | 7 | Johannes Gutenberg University MainzOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | terminated | Phase 2 | 140 | Latin American Cooperative Oncology GroupOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | terminated | Phase 1 / Phase 2 | 1 | Baylor College of MedicineOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | terminated | Phase 1 | 5 | University of UtahOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT01479348 | Imaging Study for FdCyd and THU Cancer Treatment | terminated | Early Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00350688 | Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy | terminated | N/A | 9 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT03986398 | Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement Enterocystoplasty: Prophylactic Role of Urell®, Cranberry Fruit Juice Extract (Vaccicium Macrocarpon)(Cranberry) | terminated | N/A | 10 | Hopital FochOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00226954 | Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer | terminated | Phase 2 | 23 | Stanford UniversityOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | terminated | Phase 2 | 3 | Celldex TherapeuticsINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02365207 | Intravesical BCG Administration to Patients With Invasive Bladder Cancer | terminated | N/A | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer | terminated | — | 4 | University of Southern CaliforniaOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Dec 9, 2022source: clinicaltrials